{
  "docId": "019de076-2ada-7117-9358-036add78e997",
  "docSlug": "d07954bb4369650f4386921d5f3a9e2d",
  "documentTitle": "Dare Bioscience | Results Presentation Deck | 14 slides",
  "authorId": "dare-bioscience",
  "authorName": "Daré Bioscience",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 11,
  "pageCount": 14,
  "prevPage": 10,
  "nextPage": 12,
  "slideType": "problem_statement",
  "function": "diagnose_problem",
  "density": "overcrowded",
  "nDataPoints": 5,
  "notes": "The slide uses a clear two-column layout to contrast clinical definitions with market prevalence data.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-2ada-7117-9358-036add78e997/11",
  "deckHref": "/decks/019de076-2ada-7117-9358-036add78e997",
  "deckJsonHref": "/decks/019de076-2ada-7117-9358-036add78e997.json",
  "deckAnchorHref": "/decks/019de076-2ada-7117-9358-036add78e997#slide-11",
  "components": [
    {
      "bbox": {
        "h": 0.1,
        "w": 0.9,
        "x": 0.05,
        "y": 0.85
      },
      "kind": "disclaimer",
      "text": "Diagnostic and Statistical Manual (DSM) 4th Edition Text Revision (DSM IV TR) defines FSAD as a persistent or recurrent inability to attain or maintain until completion of the sexual activity...",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ec78ef96-e7d1-48e1-93a5-91926a8dbb31",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.22,
        "w": 0.43,
        "x": 0.05,
        "y": 0.49
      },
      "kind": "list",
      "text": "Arousal disorders in women should be distinguished from a general loss of interest in sexual activity and from other sexual dysfunctions, such as orgasmic disorder (anorgasmia) and hypoactive sexual desire disorder (HSDD).",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5a6d0c32-93b4-4729-bc0a-35bfa6411fe3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.11,
        "w": 0.43,
        "x": 0.05,
        "y": 0.38
      },
      "kind": "list",
      "text": "Female Sexual Interest/Arousal Disorder (FSIAD) is defined in the DSM-5 as lack of, or significantly reduced, sexual interest/arousal.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "634d29ca-2fd2-42a0-b6f7-fed9c4a89eca",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.43,
        "x": 0.51,
        "y": 0.16
      },
      "kind": "list",
      "text": "Meta-analysis of 95 studies from 2000-2014 indicated prevalence of Female Sexual Dysfunction in premenopausal women worldwide is 41%, and difficulty with arousal alone is 23%.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8a7a91d6-b523-475a-a17c-9795925f172f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.22,
        "w": 0.43,
        "x": 0.05,
        "y": 0.16
      },
      "kind": "list",
      "text": "Female Sexual Arousal Disorder (FSAD) is characterized primarily by inability to attain or maintain sufficient genital arousal during sexual activity. Of the various types of female sexual dysfunction disorders, FSAD is most analogous to erectile dysfunction in men.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b7e1f08e-ea1a-4799-a77a-87d8e9ee1e5a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.43,
        "x": 0.51,
        "y": 0.32
      },
      "kind": "list",
      "text": "Market research estimates: 33% of US women aged 21 to 60 (~ 20 million women), experience symptoms of low or no sexual arousal. 10 million women are considered distressed and actively seeking treatment.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e5853836-3569-4219-8041-9a74d19e73ae",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.6,
        "x": 0.2,
        "y": 0.76
      },
      "kind": "title",
      "text": "There are no FDA-approved treatments for FSAD/FSIAD",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fb963881-756e-4cac-801e-285ebffe38f1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.64,
        "x": 0.18,
        "y": 0.03
      },
      "kind": "title",
      "text": "FSAD/FSIAD – The Clinical Issue & Prevalence",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "801abf04-576d-4616-b842-1fbee6c49df0",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "List presentation",
      "slug": "list-presentation",
      "agent": null,
      "layer": "slide",
      "matchId": "65603464-1f0a-4446-8010-682b0158132e",
      "evidence": "list/bullet: Arousal disorders in women should be distinguished from a general loss of interest in sexual activity and from other sexual dysfunctions, such as orgasmic disorder (anorgasmia) and hypoactive sexual desire d",
      "confidence": 0.7
    },
    {
      "name": "Problem Statement Canvas",
      "slug": "problem-statement-canvas",
      "agent": "Architect",
      "layer": "slide",
      "matchId": "608fac4f-903f-48e0-bf2e-344852137b54",
      "evidence": "list/bullet: Female Sexual Arousal Disorder (FSAD) is characterized primarily by inability to attain or maintain sufficient genital arousal during sexual activity.",
      "confidence": 0.8
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 11,
      "from": 11,
      "beatId": "ab4b26fa-aeda-413d-a170-d5556603ae0c",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Problem",
      "beatSlug": "sequoia-pitch-problem",
      "evidence": "Slide 11 states 'There are no FDA-approved treatments for FSAD/FSIAD'",
      "position": 0,
      "confidence": 0.8,
      "parentBeatName": "Complication",
      "parentBeatSlug": "complication"
    }
  ],
  "loops": [
    {
      "to": 14,
      "from": 11,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "a5364aee-83ce-4e62-88bd-2a73446e65eb",
      "evidence": "The presentation emphasizes the lack of FDA-approved treatments for FSAD/FSIAD and the potential of Daré Bioscience's products",
      "position": 0,
      "objective": "Highlight the importance of Daré Bioscience's products in addressing unmet medical needs",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.7,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}